The Level of FGF 21 as a New Risk Factor for the Occurrence of Cardiometabolic Disorders amongst the Psoriatic Patients

Fibroblast growth factors 21 and 23 are used as markers of cardiometabolic disorders which are common comorbidities in psoriasis. The study aimed to evaluate the serum level of these factors in psoriatic patients and elucidate the possible interplay between disease activity, metabolic or inflammator...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiluk, Paulina, Baran, Anna, Kaminski, Tomasz W., Maciaszek, Magdalena, Flisiak, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947480/
https://www.ncbi.nlm.nih.gov/pubmed/31847236
http://dx.doi.org/10.3390/jcm8122206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947480/
https://www.ncbi.nlm.nih.gov/pubmed/31847236
http://dx.doi.org/10.3390/jcm8122206

Ejemplares similares